0.00Open0.00Pre Close0 Volume0 Open Interest25.00Strike Price0.00Turnover0.00%IV9.17%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma13.09Leverage Ratio--Theta--Rho--Eff Leverage--Vega
MeridianLink Stock Discussion
Reported strong third-quarter results and continues to benefit from the accelerated digital transformation of financial services. The Company continues to add new quality customers and expand its relationships with existing customers in a wide range of markets, including lenders, financial service providers and information providers. Continue to expand further into adjacent markets and expand its product offering with increasing services and enhanced data validation, including the ability to provide repeated background checks to reduce risk and add new features to its advanced QuickApp tool to enable its customers to better serve their customers
$Elicio Therapeutics (ELTX.US)$ $Candel Therapeutics (CADL.US)$ $Context Therapeutics (CNTX.US)$ $Dole plc (DOLE.US)$ $Duolingo (DUOL.US)$ $MeridianLink (MLNK.US)$ $PowerSchool (PWSC.US)$ $Snap One (SNPO.US)$ $Icosavax (ICVX.US)$ $Preston Hollow Community Capital (PHCC.US)$ $Rallybio (RLYB.US)$ $Riskified (RSKD.US)$
No comment yet